growth

April 23, 2024

Earnings call: Getinge reports steady Q1 growth, maintains full-year outlook

Getinge AB (GETI B), a leading global provider of medical technology products and solutions, reported a 5.2% increase in sales for the first quarter of 2024, with a steady organic sales performance despite previous year's high comparative figures from COVID-19 impacts in China. The company's order intake rose by 7.8%, showing organic growth across all business areas and regions.

Read More
April 23, 2024

Earnings call: ServisFirst Bancshares reports strong Q1 growth

ServisFirst Bancshares, Inc. (NYSE:SFBS) began the first quarter of 2024 on a positive note, showcasing significant growth in net loans and a robust loan pipeline. The bank's Chief Credit Officer, Henry Abbott, reported an improvement in credit quality, while the Chief Financial Officer, Kirk Pressley, noted the highest net interest income since Q1 of 2023 and an optimistic outlook for the year. The bank is preparing to enter a new market and has strengthened its team with nine new bankers. Despite a rise in non-performing assets, which was attributed to a single credit, ServisFirst remains well-positioned against its competitors in this area. The bank's liquidity position appears solid, with expectations of deposit growth and a lift in yields on earning assets. ServisFirst's customer base is expanding, buoyed by a more optimistic outlook and receding recession concerns.

Read More
April 23, 2024

Earnings call: SAP sees record cloud growth in Q1 2024

SAP SE (ETR:SAPG) (SAP) reported a robust start to 2024, with its first-quarter earnings showcasing a significant surge in cloud revenue and backlog, alongside a healthy increase in operating profit. The company's cloud revenue climbed by 25% to EUR 3.9 billion, while the current cloud backlog expanded by 28% to a record EUR 14.2 billion. Operating profit rose by 19% to EUR 1.5 billion, reflecting strong performance across various regions and a strategic focus on cloud and AI-driven growth.

Read More
April 22, 2024

India Pharma Sector Set for Robust Growth Amidst Margin Concerns

As the Q4 FY24 earnings season is going on, Goldman Sachs (NYSE:GS) analysts have recalibrated their projections for the Indian pharmaceutical sector, factoring in a spectrum of variables from monthly sales data to currency fluctuations. Notably, the sector continues to trade at valuations exceeding one standard deviation above its five-year average, largely propelled by the resilience of major players like Sun Pharma (NS:SUN), Cipla (NS:CIPL), and Divi’s Laboratories.

Read More